ESG permeates pharmaceutical pricing strategy
Click here to access GlobalData’s Market Access and Pricing Services
Healthcare Policy
Canada’s PMPRB reform delays add uncertainty
Click here to access GlobalData’s Market Access and Pricing Services
By
Industry hopes dashed after EU compromises to squeeze through cross border HTA agreement
Click here to access GlobalData’s Market Access and Pricing Services
By
Vaccine hesitancy boosts risks from vaccine nationalism
Click here to access GlobalData’s Market Access and Pricing Services
By
Biden administration scores first legislative win for pharmaceutical pricing reform
Click here to access GlobalData’s Market Access and Pricing Services
By
AMNOG ten years on: Impact on the Europe top 5 price level hierarchy
Click here to access GlobalData’s Market Access and Pricing Services
By
Pharma and healthcare top 10: What to expect in 2021 and beyond
Click here to access GlobalData’s Market Access and Pricing Services
US drug prices could be drastically impacted by Most Favored Nation executive order
Click here to access GlobalData’s Market Access and Pricing Services